Area of research
Pulmonary and Respiratory Medicine · Pathology and Forensic Medicine
Research interest
Research interests include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Systemic Sclerosis and Related Diseases, Chronic Obstructive Pulmonary Disease (COPD) Research, and Pulmonary Hypertension Research and Treatments.
A phase 1 pharmacokinetics study of deupirfenidone (LYT-100) in healthy older adults.
Progressive pulmonary fibrosis: the importance of identification and intervention.
Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trial.
Circulating biomarkers in subjects with progressive pulmonary fibrosis: data from the INBUILD trial.
Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial.
Prognostic biomarkers for idiopathic pulmonary fibrosis: findings from ISABELA clinical trials.
Reply: From the authors of the ERS/ATS statement on the international multidisciplinary classification of the interstitial pneumonias.
Genome-wide association study of Idiopathic Pulmonary Fibrosis susceptibility using clinically-curated European-ancestry datasets
Prioritizing Therapeutic Targets for Interstitial Lung Disease: A Causal Mediation Analysis
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis
Nerandomilast in Patients with Progressive Pulmonary Fibrosis
Update of the International Multidisciplinary Classification of the Interstitial Pneumonias: An ERS/ATS Statement
Nerandomilast in Patients with Progressive Pulmonary Fibrosis.
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.
Efficacy and Safety of Admilparant, an LPA<sub>1</sub> Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.
Fibrosis: cross-organ biology and pathways to development of innovative drugs.
Update of the international multidisciplinary classification of the interstitial pneumonias: an ERS/ATS statement.
Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation
Publisher Correction: Fibrosis: cross-organ biology and pathways to development of innovative drugs.
Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation.
Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease.
Kappa and Mu Opioid Receptors in Chronic Cough: Current Evidence and Future Treatment.
Phase 2 study design and analysis approach for BBT-877: an autotaxin inhibitor targeting idiopathic pulmonary fibrosis.
Reply: The rationale for distinguishing RB-ILD and AMP.
Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis
LB0003 EFFICACY AND SAFETY OF NERANDOMILAST IN PATIENTS WITH AUTOIMMUNE DISEASE–RELATED PROGRESSIVE PULMONARY FIBROSIS: SUBGROUP ANALYSIS OF THE FIBRONEER-ILD TRIAL
Phase III FIBRONEER-IPF Trial of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis
Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis.
Basement membrane repair response biomarker PRO-C4 predicts progression in idiopathic pulmonary fibrosis: analysis of the PFBIO and PROFILE cohorts.
ASPIRE Trial in Idiopathic Pulmonary Fibrosis: A Patient Experience-focused Phase 2b Randomized, Double-blind, Placebo-controlled, Multicenter Trial of the Novel Angiotensin II Type 2 Receptor Agonist Buloxibutid